Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | MAOB | P27338 | 3/20 | 0.54 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.49 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.48 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.48 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.48 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.47 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL509590 | 0.84 | ALDH1A1 (0.47) | P4HTMALDH1A1NPC1RAB9AFFAR1 | |
| SCHEMBL15776018 | 0.84 | CYP4F2 (0.53) | P4HTMMAOB | |
| SCHEMBL9263293 | 0.82 | ALDH1A1 (0.50) | ALDH1A1NPC1RAB9ACASP3SENP8 | |
| SCHEMBL13034091 | 0.82 | ALDH1A1 (0.76) | ALDH1A1MAOBNR4A1NR4A2NR4A3 | |
| SCHEMBL3300820 | 0.81 | PDE3B (0.42) | ALDH1A1FFAR1L3MBTL1HTTACACB | |
| SCHEMBL4166459 | 0.81 | P4HTM (0.63) | P4HTMMAOBNR4A1NR4A2NR4A3 | |
| SCHEMBL11375563 | 0.80 | ALDH1A1 (0.44) | ALDH1A1NPC1RAB9AGPR55LMNA | |
| SCHEMBL1572841 | 0.80 | P4HTM (0.54) | P4HTMALDH1A1MAOBNPC1RAB9A | |
| SCHEMBL1059319 | 0.80 | ALDH1A1 (0.44) | ALDH1A1NPC1RAB9ASMN1; SMN2HTT | |
| SCHEMBL11878371 | 0.80 | P4HTM (0.49) | P4HTMALDH1A1MAOBNR4A1NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2925762-B1 | TRIAZOLO-PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM | SUNOVION PHARMACEUTICALS INC (US) | 2017-07-05 | — | — | EP | disclosed |
| US-9670230-B2 | Heteroaryl compounds and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-9670230-B2 | Heteroaryl compounds and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20150291626-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2015-10-15 | — | — | US | disclosed |
| EP-2925762-A1 | TRIAZOLO-PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM | Sunovion Pharmaceuticals Inc. (US) | 2015-10-07 | — | — | EP | disclosed |
| WO-2014085284-A1 | TRIAZOLO-PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM | SUNOVION PHARMACEUTICALS INC. (US) | 2014-06-05 | — | — | WO | disclosed |
| US-8609699-B2 | Oxotetrahydrofuran-2-yl-benzimidazole derivative | MSD K.K. (JP) | 2013-12-17 | — | — | US | disclosed |
| EP-2328892-B1 | OXOTETRAHYDROFURAN-2-YL-BENZIMIDAZOLE DERIVATIVE | MSD KK (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-20110144162-A1 | OXOTETRAHYDROFURAN-2-YL-BENZIMIDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-06-16 | — | — | US | disclosed |
| EP-2328892-A1 | OXOTETRAHYDROFURAN-2-YL-BENZIMIDAZOLE DERIVATIVE | MSD K.K. (JP) | 2011-06-08 | — | — | EP | disclosed |
| WO-2007099323-A2 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-09-07 | — | — | WO | disclosed |
| WO-2007099317-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-09-07 | — | — | WO | disclosed |
| US-6630488-B1 | Quinolizinones as integrin inhibitors | BIOCHEM PHARMA, INC. (CA) | 2003-10-07 | — | — | US | disclosed |
| EP-1115724-A1 | QUINOLIZINONES AS INTEGRIN INHIBITORS | Shire Biochem Inc. (CA) | 2001-07-18 | — | — | EP | disclosed |
| WO-2000017197-A1 | QUINOLIZINONES AS INTEGRIN INHIBITORS | BIOCHEM PHARMA INC. (US) | 2000-03-30 | — | — | WO | disclosed |
| EP-0313630-B1 | SUBSTITUTED 2-ACYLPYRIDIN-ALPHA-(N)-HETARYLHYDRAZONES AND MEDICAMENTS CONTAINING SAME | DEUTSCHES AUSSÄTZIGEN HILFSWERK E.V. (DE) | 1992-09-16 | — | — | EP | disclosed |
| US-5084458-A | Bactericides, malaria and antitumor agents | SCHAPER KLAUS JUERGEN (DE) | 1992-01-28 | — | — | US | disclosed |
| US-4997835-A | Bactericides, malaria, antitumor | SCHAPER KLAUS JUERGEN (DE) | 1991-03-05 | — | — | US | disclosed |
| EP-0313630-A1 | SUBSTITUTED 2-ACYLPYRIDIN-ALPHA-(N)-HETARYLHYDRAZONES AND MEDICAMENTS CONTAINING SAME. | DEUTSCHES AUSSATZIGEN HILFSWER (DE) | 1989-05-03 | — | — | EP | disclosed |
| US-3952101-A | BETA ADRENERGIC STIMULANT | SMITHKLINE CORPORATION (US) | 1976-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144162-A1 | OXOTETRAHYDROFURAN-2-YL-BENZIMIDAZOLE DERIVATIVE | GCK, GCKR, KHK | P4HTM 1139/4885ALDH1A1 823/4885MAOB 2104/4885 |
| US-20150291626-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, GPR119, NLN | P4HTM 1282/4885ALDH1A1 560/4885MAOB 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.